This article is the sixth in a series of bi-weekly columns focusing on the area of "high-throughput biology," or new techniques for high-volume cell-based screening and imaging that biopharma is using to validate targets generated through genomics or proteomics, screen for toxicity, and replace other traditional assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.